Stock CAPR CAPRICOR THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Highlights Capricor Therapeutics, Inc.

Equities

CAPR

US14070B3096

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-06-13 pm EDT 		5-day change 1st Jan Change
5.29 USD +4.55% Intraday chart for Capricor Therapeutics, Inc. -3.47% +8.18%
Jun. 11 Sector Update: Health Care Stocks Decline Tuesday Afternoon MT
Jun. 11 Capricor Says FDA Grants Pre-BLA Meeting Request for Duchenne Muscular Dystrophy Treatment; Shares Rise MT

Highlights

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Sector Update: Health Care Stocks Decline Tuesday Afternoon
MT
Capricor Says FDA Grants Pre-BLA Meeting Request for Duchenne Muscular Dystrophy Treatment; Shares Rise
MT
Capricor Therapeutics Announces Positive Type-B Meeting with FDA for CAP-1002 Program for Duchenne Muscular Dystrophy with an Aim to Expedite BLA Pathway
CI
Capricor Therapeutics Announces Positive 3-Year Efficacy Results from Hope-2 Open Label Extension Study of CAP-1002 in Duchenne Muscular Dystrophy
CI
Earnings Flash (CAPR) CAPRICOR THERAPEUTICS Posts Q1 Revenue $4.9M, vs. Street Est of $9.7M
MT
Capricor Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Capricor Therapeutics, Inc. to Present Exosome Platform Updates At the American Society of Gene and Cell Therapy 27Th Annual Meeting
CI
Capricor Therapeutics Gets Another Type-B Meeting With FDA for Duchenne Muscular Dystrophy Investigational Drug
MT
Capricor Therapeutics Announces Positive Type-B Meeting with FDA for CAP-1002 Program for Duchenne Muscular Dystrophy
CI
Capricor Therapeutics, Inc. to Present Positive 24-Month Results from its HOPE-2 Open-Label Extension Study at 2024 Muscular Dystrophy Association Clinical & Scientific Conference
CI
Earnings Flash (CAPR) CAPRICOR THERAPEUTICS Posts Q4 Revenue $12.1M, vs. Street Est of $10.6M
MT
Capricor Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
CI
Capricor Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Capricor Secures Meeting With FDA on CAP-1002 Manufacturing Plans; Shares Rise
MT
Capricor Therapeutics Announces Manufacturing Scale-Up of Cap-1002 Production At New San Diego Facility as It Continues Plans Toward Commercialization
CI
Capricor Therapeutics Shares Rise 7% After Collaboration for Covid-19 Vaccine
DJ
Capricor Therapeutics Announces Collaboration with the National Institutes of Health for Clinical Trial of Novel Exosome-Based Multivalent Vaccine for SARS-CoV-2
CI
Capricor Therapeutics Announces Continuation of Phase 3 Hope-3 Trial of CAP-1002 in Duchenne Muscular Dystrophy Based on Completion of Interim Futility Analysis
CI
Earnings Flash (CAPR) CAPRICOR THERAPEUTICS Reports Q3 Revenue $6.2M, vs. Street Est of $3.17M
MT
Capricor Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. CAPR Stock
  4. News Capricor Therapeutics, Inc.
  5. Highlights